Development and deployment of COVID-19 vaccines forthose most vulnerable

Wayne C. Koff, Theodore Schenkelberg, Tere Williams, Ralph S. Baric, McDermott Adrian McDermott, Cheryl M. Cameron, Mark J. Cameron, Matthew B. Friemann, Gabriele Neumann, Yoshihiro Kawaoka, Alyson A. Kelvin, Ted M. Ross, Stacey Schultz-Cherry, Timothy D. Mastro, Frances H. Priddy, Kristine A. Moore, Julia T. Ostrowsky, Michael T. Osterholm, Jaap Goudsmit

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.

Original languageEnglish (US)
Article numbereabd1525
JournalScience Translational Medicine
Volume13
Issue number579
DOIs
StatePublished - Feb 3 2021

Bibliographical note

Funding Information:
W.C.K., T.S., and J.G. are supported by the Human Vaccines Project donor network. A.M. is supported by NIAID. C.M.C., M.J.C., and A.A.K. are funded by the Canadian Institutes for Health Research Rapid Response Grant for COVID-19. Y.K. is supported by a Research Program on Emerging and Re-emerging Infectious Diseases from AMED (19fk0108113). Y.K. and G.N. are supported by NIAID (grant no. HHSN272201400008C). T.M.R. is supported by an Emory-UGA-CEIRS grant (no. HHSN272201400004C). S.S.-C. is supported in part by ALSAC and by NIAID (grant no. HHSN272201400006C). T.M.R. and S.S.-C. are also supported by NIAID (grant no. 75N93019C00052). M.T.O., K.A.M., and J.T.O. are supported by the Wellcome Trust and by NIAID (grant no. HHSN272201400006C). Y.K. has received funding from Bharat Biotech.

Publisher Copyright:
Copyright © 2021 The Authors.

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Fingerprint Dive into the research topics of 'Development and deployment of COVID-19 vaccines forthose most vulnerable'. Together they form a unique fingerprint.

Cite this